Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval, making it the first precision medicine combo for patients with BRCA2-mutated metastatic ...
Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results